GlaxoSmithKline News

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

Benzinga13:13 ET

Barclays Remains a Hold on GlaxoSmithKline (GSK)

TipRanksDec 12 02:35 ET · Ratings

Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More

Moomoo NewsDec 11 18:00 ET · Markets

Anaptys Scraps Development of ANB032, Stock Plunges 33%

Seeking AlphaDec 11 11:52 ET

TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45

Moomoo NewsDec 11 10:32 ET · Ratings

GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

Zacks Dec 11 09:30 ET

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

BenzingaDec 10 13:14 ET

India Drug Delivery Devices Market 2024, With Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma

Yahoo FinanceDec 10 07:25 ET

GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments

WSJDec 10 03:24 ET

Glaxosmithkline (GSK.US) drugs reduce the risk of death by 42% in multiple myeloma studies.

Glaxosmithkline (GSK.US) reported that a study shows its drug belantamab mafodotin can reduce the risk of death for patients with multiple myeloma at first relapse or post-relapse by 42%.

Zhitong FinanceDec 10 01:20 ET

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT NewswiresDec 9 15:56 ET

Sector Update: Health Care

MT NewswiresDec 9 15:32 ET

GSK's DREAMM-7 Trial Shows Sustained Overall Survival Benefit For Belantamab Mafodotin Combination Versus Daratumumab Combination; Benefit Seen Early And Maintained Through Follow-up, Reducing The Risk Of Death By 42% In Multiple Myeloma At Or After...

BenzingaDec 9 13:42 ET

GSK: Data Compares With Competitor Drug Johnson & Johnson's Darzalex

Dow JonesDec 9 13:30 ET

GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care

Dow JonesDec 9 13:30 ET

GSK: Data Is For Patients With Multiple Myeloma at or After First Relapse

Dow JonesDec 9 13:30 ET

GSK: Blenrep Is Treatment for Relapsed/Refractory Multiple Myeloma

Dow JonesDec 9 13:30 ET

GSK: Data Projects Patients on Blenrep Combination To Survive Nearly Three Years Longer Compared to Standard of Care

Dow JonesDec 9 13:30 ET

GSK: Blenrep Combination Late-Stage Trial Reduced Risk of Death by 42% in Patients With Multiple Myeloma at or After First Relapse

Dow JonesDec 9 13:30 ET

GSK Gets Positive Results in Blood-Cancer Drug Trial

WSJDec 9 13:30 ET